Omadacycline: A Tetracycline with Potential for Managing Tuberculosis

Studies using an in vitro model of TB suggest that omadacycline is a promising component of treatment.

The treatment of tuberculosis (TB) is hampered by drug resistance and lengthy regimens. While shorter-duration regimens have emerged, new drugs (or repurposed old ones) against TB are always in demand. Omadacycline (OMC), the newest-generation tetracycline, has shown potential against mycobacterial infections. Now, researchers have evaluated OMC's activity against two TB strains (one multidrug-resistant [MDR]) using a pharmacodynamic/pharmacokinetic (PK/PD) in vitro hollow fiber system model.

The minimum inhibitory concentration (MIC) of OMC was 16 mg/L against both strains but was 4 mg/L when OMC was supplemented to account for its degradation in solution (50% in 24 hours). In the hollow-fiber system, OMC showed killing at all exposures, wi…

Reviewing Author

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases